Heron Therapeutics, Inc. /DE/ splits its revenue into 4 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was CINVANTI at $96.8 million, 62% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
151
|
155
|
144
|
127
|
108
|
86
|
89
|
146
|
77
|
—
|
—
|
| CINVANTI |
89
-10.3%
share 59.0%
|
97
-3.3%
share 62.5%
|
100
+5.5%
share 69.4%
|
95
+8.7%
share 74.7%
|
87
+18.7%
share 81.0%
|
74
-16.3%
share 85.1%
|
88
-33.6%
share 99.1%
|
132
+135.2%
share 90.5%
|
56
share 72.5%
|
—
|
—
|
| ZYNRELEF |
43
+39.4%
share 28.5%
|
38
+49.0%
share 24.6%
|
26
+44.1%
share 17.7%
|
18
+73.9%
share 14.0%
|
10
+248.7%
share 9.5%
|
3
share 3.4%
|
—
|
—
|
—
|
—
|
—
|
| Aponvie |
15
+86.2%
share 9.6%
|
12
+156.1%
share 7.5%
|
5
+224.8%
share 3.1%
|
1
share 1.1%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| SUSTOL |
4
-62.5%
share 2.9%
|
9
-39.9%
share 5.5%
|
14
+8.3%
share 9.8%
|
13
+27.6%
share 10.3%
|
10
+3.2%
share 9.5%
|
10
+1104.7%
share 11.5%
|
1
-94.0%
share 0.9%
|
14
-35.2%
share 9.5%
|
21
share 27.5%
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HRTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 818033
- Former names
- AP PHARMA INC /DE/ (until Jan 7, 2014); ADVANCED POLYMER SYSTEMS INC /DE/ (until Apr 6, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.